Chlamydia is the most common sexually transmitted disease in the US and causes infertility, ectopic pregnancy and pelvic inflammatory disease if left untreated.
The study, published in the journal Infection and Immunity, indicates that exposing the gut first to chlamydia is a novel avenue to explore in preventing the genital infection.
However, when the genital tract is the site of initial chlamydia exposure, a different outcome may result.
In this scenario, genital chlamydia spreads to the gut and induces responses that promote further disease in the genital tract.
Also Read
Human exposure to chlamydia is unpredictable, perhaps coming through genital or non-genital sexual contact with an infected partner and perhaps via contact with contaminated materials.
The researchers utilised a mouse model that is a controlled way to study chlamydia transmission.
The team found that if the gut is the first site to be colonised by chlamydia bacteria, then the mice are immunised against further disease.
The gut infection is benign. However, if the genital tract is the first to be infected, the resulting disease is harmful, according to the researchers.
"If you are exposed to chlamydia in the GI tract first, it's a vaccine, but if you are exposed in the genital tract first, you may have enhanced disease," Zhong said.
Zhong is exploring the possibility that Chlamydia trachomatis, the bacterium that causes chlamydia, could be delivered orally as a vaccine.
"We take probiotics for our GI health. In the future, we may add chlamydia as a probiotic for the gut. Once the bacteria are established in the GI tract, they don't spread," the researcher said.
Disclaimer: No Business Standard Journalist was involved in creation of this content